Over-activity of the enzyme HDAC6 in the nerve ends exacerbates the symptoms of the neurogenerative condition ALS, demonstrated in fruit-flies by scientists at VIB and KY Leuven.

Amyotrophic Lateral Sclerosis – a degenerative process In patients with ALS, the nerve cells that allow for the synaptic transmission die off. Synaptic transmission is the transmission of signals to the muscles, which is essential for the coordination of the muscles. ALS falls under the collective term of neurodegenerative conditions, which includes diseases such as Parkinson's disease. It is a progressive, debilitating neurological disease for which there is currently no treatment available. ALS patients are very aware of the entire process. ALS patients often opt for euthanasia in order to avoid suffocating to death as the respiratory muscles also fail in the end.
Over-activity HDAC6 Katarzyna Miskiewicz, Liya Jose and Patrik Verstreken have studied how this type of nerve cell becomes defective in fruit-flies that express a form of ALS. Fruit-flies are a very suitable model organism for neurological research. In the case of ALS, the specific defect is located at the nerve endings, where the investigators discovered an over-activity of the enzyme HDAC6. This over-activity of HDAC6 is a cause of the disrupted synaptic transmission, resulting in a symptomatic exacerbation of the disease. In order to stop this process, it would – in theory – be helpful to combat the over-activation of the enzyme HDAC6 in order to return to "normal" activity of the HDAC6 enzyme.
Not only HDAC6 defect Although this discovery may provide a possible avenue for symptomatic ALS treatment, it should be noted that the HDAC6 defect is probably one of the many enzyme defects that play a role in ALS. Previously, Patrik Verstreken and Wim Robberecht (VIB/KU Leuven) demonstrated that another enzyme that is involved in ALS – Elp3 – acts on the same process at the nerve endings as HDAC6. Ideally, the various avenues should all be studied in the hope of finding a treatment for ALS in the future.
Source-Eurekalert